1.中古義雄,(賴逢甲 譯),良導絡理論的研究,p1-11,1985
2.中古義雄,(賴逢甲 譯),良導絡臨床指引p1-10,1985
3.中古義雄,(賴逢甲 譯),良導絡診斷法p1-6,1985
4.翁清松,王智濃,胡威志,孫茂峰 (2002), “新型良導絡應用於下背痛針灸療效之評估”, 中國醫藥科學雜誌, Vol.3 , No.1 .5.辛紹祺,2002,《良導絡量測系統應用於評估麻醉病患之穴位刺激作用》,中原大學醫學工程研究所碩士論文6.林巧瑩,改良式雷射針灸儀之研究發展及用於疼痛療效之估,中原大學醫工研究所論文,20057.陳彥廷,超長波刺激足三里穴,對高血壓患者之療效評估,中原大學醫工研究所論文,20028.謝孟蓉,八週浸泡溫泉對人體生物能量與心臟自律神經活動狀態之影響,國立體育學院運動傷害防護研究所,20049.盧裕文,以良導絡儀測定評估遠紅外線對人體健康之影響,國立成功大學電機工程學系研究所論文,200310.謝文祥,以良導絡評估不同電刺激模式於酸痛症之療效,中原大學醫學工程研究所論文,200211.淑月、黃崇博、余杰、翁清松,探討正常人與高血壓病患之穴位電阻抗,醫學工程研究成果發表會論文集,2005
12.林淑月、許智傑、黃崇博、余杰、翁清松、何豐名、陳瑞昌、陳治平,“以不同的分析方法探討正常人與脂肪肝患者手部反應點電位之差異性”, 先進工程期刊,2006
13.林淑月、許智傑、黃崇博、余杰、翁清松、何豐名、陳瑞昌、陳治平,手部穴位電阻抗探討正常人與脂肪肝病患特徵之評估及應用,2006工程科技與中西醫學應用研討會論文集,p288-291,2006
14.張成國 林昭庚等編著,中西醫針灸學,台中,私立中國醫藥學院針灸研究中心出版,p37.1982
15.陳華 編著,中醫的科學原理,台北,台灣商務印書館出版,p89-90,1999
16.魏大森 電針療法原理及臨場應用 , 中華針灸醫學會雜誌,P8,1998
17.王智濃 翁清松 張詠嫻 林昭庚 雷射針灸、超音波針灸與傳統針灸之刺激反應研究,中華針灸醫學會雜誌,P14,1999
18.王仁輝 超音波針灸儀之研發及其可行性之研究,中原大學醫工程所碩士論文,p8.1999
19.Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004; 116: 337–350.
20.Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension. 2004; 43: 36–40.
21.Regulation in a rat model of visceral obesity and hypertension. Hypertension. 2004; 43: 383–387.
22.Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004; 44: 12–19.
23.Wu CC, Hwang YS: Structural and functional changes of the heart in hypertension --- an echocardiographic study. J Formosan Med Assoc 1981; 80: 1169-77.
24.Hsieh YY: The diagnosis of left ventricular hypertrophy in hypertensive patients by electrocardiography and echocardiography. J Formosan Med Assoc 1978; 77: 165-73.
25.Liu CZ, Jan KM, Luo HS, Chiou HC, Chen PH, Chen CM: Ambulatory electrocardiographic findings in patients with essential hypertension vs. normal subjects without apparent heart diseases. J Formosan Med Assoc 1985; 84: 571-8.
26.Goldstei D. E., Parker K. M., England J. D.: Clinical application of glycosylated hemoglobin measuremeny. Diabetes. 1982, 31(Suppl 3), 70-78
27.Roberts W. L.,. Frank E. L, Moulton L., Papadea C., Noffsinger J., Ou C. : Effects of nine hemoglobin variants on five glycohemoglobin methods. Clin. Chem. 2000, 46, 569-572.
28.Schnedl W. J.,. Krause R, Halwaches-Baumann G., Trinker M., Lipp R. W., Krejs G. J. : Evaluation of HbA1c determination methods in patients with hemoglobinpathies. Dibetes Care 2000, 23, 339-344.
29.Rocchini AP, Yang JQ, Gokee A. Hypertension and insulin resistance are not directly related in obese dogs. Hypertension. 2004; 43: 1011–1016.
30.Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004; 53: 2060–2066.
31.Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002; 359: 1430-1432.
32.Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. F AM Coll Cardiol. 2001; 37: 379-385.
33.Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl F Med. 2002; 347: 161-167.
34.Bulletin of Association of Laboratory Medicine. R. O. C2004;Vol.19 No.5
35.Hsieh BS, Chen WY, Yen TS, Hsu HC: Renal prostaglandin E in renoparenchymal hypertension. J Formosan Med Assoc 1984; 83: 627-33.
36.Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003; 41: 625–633.
37.Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004; 43: 41–47.
38.Yang MCM, Kuo JS, Pang PKT: Mechanisms of the vascular action of parathyroid hormone. J Pharm Exp Ther 1990; 252: 840-4.
39.Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertention Ann Intern Med. 2003;139: 761-766.
40.Anderson KM, Casteli WP, Levy D. Cholesterol and motality. 30 years of follow-up from the Framingham study. JAMA. 1987; 257: 2176-2180.
41.Borghi C, Dormi A,Veronesi M, Sangiorgi Z, Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J.2004; 148 285-292.
42.Executive Summary of The eport of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluatio, and Treatment of Hight Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
43.Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertention. 2003; 42: 43-48.
44.Gloriso N, Troffa C, Filigheddu F, Soro A, Parpaglia PP,Collatina S, Pahor M. Effect of the 3-hydroxy-3methylglutaryl(HMG)-coenzymeA(CoA) reductase inhibitors on blood pressure in patients with essential hypertention and primary hypercholesterolemia. Hypertention. 1999; 34 1281-1286.
45.中醫診斷學173-175,1980
46.中醫診斷學180-181,1980
47.山東醫學院學報 P89-91 1995 19卷 2期
48. 田安然 編著, 保固你的腎,文經出版社,p.25-28, 2000
49 .田安然 編著, 保固你的腎 ,文經出版社,p.32-33,2000
50. 田安然 編著, 保固你的腎 ,文經出版社,p.38-39,2000
51. 田安然 編著, 保固你的腎 ,文經出版社,P. 41,2000
52. 鮑景隆等編著,手穴手紋診治秘訣,正中書局
54. Insightful Miner 7.0,2005,Insightful Miner Company
53. 林震岩編著, 多變量分析SPSS的操作與應用,智勝出版社,2007
55. 中醫經�G學全書 大臺北出版社,p41,1988
56. 中醫經�G學全書 大臺北出版社,p57,1988
57. 鄺安�J主編,高血壓研究,知音中西結合研究叢書 p71-78
58. 鄺安�J主編,高血壓研究,知音中西結合研究叢書 p108-109